Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323344 | 1.00 | SLC6A4 (0.53) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3324955 | 0.86 | SLC6A4 (0.53) | SLC6A4HTR6HTR2CHTR2BSLC6A2 | |
| SCHEMBL3329884 | 0.86 | SLC6A4 (0.53) | SLC6A4HTR6HTR2CHTR2BSLC6A2 | |
| SCHEMBL3324998 | 0.86 | SLC6A4 (0.48) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3324991 | 0.86 | SLC6A4 (0.48) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3324210 | 0.85 | SCN9A (0.44) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3320864 | 0.85 | SCN9A (0.44) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3324066 | 0.82 | SLC6A4 (0.45) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3324061 | 0.82 | SLC6A4 (0.45) | SLC6A4HTR6SCN9AHTR2CHTR2B | |
| SCHEMBL3321373 | 0.82 | MAP2K1 (0.43) | SLC6A4HTR6SCN9AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | claimed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | SLC6A4 1898/4885HTR6 832/4885SCN9A 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.